National Institutes of Health (NIH) today announced that next week it will begin a phase 1 clinical trial of an #Ebola #vaccine co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline to test safety and immune response in healthy volunteers. The trial has been expedited in response to the ongoing Ebola virus outbreak in West Africa. It is not a treatment, but a vaccine intended to prevent healthy people from contracting the disease.
Posted on: Fri, 29 Aug 2014 12:34:48 +0000
Trending Topics
Recently Viewed Topics
© 2015